Drawing based on the description in the official product monograph. No photo yet.
“500 mg Tablets are supplied as peach, capsule-shaped, biconvex, film-coated tablets. Engraved "APO" on one side and "LFX 500" on the other side”
APO LFX 500 pill
Pill with imprint APO LFX 500 is orange, capsule and has been identified as Levofloxacin Hemihydrate 500 mg. It is used for bronchitis, urinary tract infections (UTIs) and pneumonia. It is supplied by Apotex Inc.
Sold in Canada
Levofloxacin Hemihydrate 500 mg
- Brand
- Apo-Levofloxacin
- Imprint
- APO LFX 500
- Strength
- 500 mg
- Used for
- Bronchitis, urinary tract infections (UTIs) and pneumonia
- Color
- Orange
- Shape
- Capsule / oblong
- Form
- Tablet
- Manufacturer
- Apotex Inc
- Drug class
- Antibiotic (fluoroquinolone)
- Sold in
- Canada
- DIN
- 02284715
Source: Health Canada's Drug Product Database and the official product monograph. Last checked .
Report a mistake
What is Levofloxacin used for?
Levofloxacin is used for bronchitis, urinary tract infections (UTIs), pneumonia and skin infections.
- Medicine type
- Antibiotic (fluoroquinolone)
Official uses from the US prescribing label
Nosocomial Pneumonia
Levofloxacin tablets are indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae,or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosais a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended.
Community-Acquired Pneumonia: 7 to 14 day Treatment Regimen
Levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae(including multi-drug-resistant Streptococcus pneumoniae[MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila,or Mycoplasma pneumoniae.
MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2 ndgeneration cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.
Community-Acquired Pneumonia: 5-day Treatment Regimen
Levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae(excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae,or Chlamydophila pneumoniae.
Complicated Skin and Skin Structure Infections
Levofloxacin tablets are indicated in adult patients for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes,or Proteus mirabilis.
Uncomplicated Skin and Skin Structure Infections
Levofloxacin tablets are indicated in adult patients for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus,or Streptococcus pyogenes.
Chronic Bacterial Prostatitis
Levofloxacin tablets are indicated in adult patients for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis,or methicillin-susceptible Staphylococcus epidermidis.
Inhalational Anthrax (Post-Exposure)
Levofloxacin tablets are indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracisin adults and pediatric patients, 6 months of age and older. The effectiveness of levofloxacin tablets is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin tablets have not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin tablets in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin tablets therapy should only be used when the benefit outweighs the risk.
Plague
Levofloxacin tablets are indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis( Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older.
Efficacy studies of levofloxacin tablets could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals.
Complicated Urinary Tract Infections: 5-day Treatment Regimen
Levofloxacin tablets are indicated in adult patients for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae,or Proteus mirabilis.
Complicated Urinary Tract Infections: 10-day Treatment Regimen
Levofloxacin tablets are indicated in adult patients for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis,or Pseudomonas aeruginosa.
Acute Pyelonephritis: 5 or 10-day Treatment Regimen
Levofloxacin tablets are indicated in adult patients for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia.
Uncomplicated Urinary Tract Infections
Levofloxacin tablets are indicated in adult patients for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae,or Staphylococcus saprophyticus.
Because fluoroquinolones, including levofloxacin tablets, have been associated with serious adverse reactions and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin tablets for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options.
Acute Bacterial Exacerbation of Chronic Bronchitis
Levofloxacin tablets are indicated in adult patients for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae,or Moraxella catarrhalis.
From the FDA-approved label on DailyMed (published Sep 02, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- Your pill shows APO LFX 500. The parts can be split between the two sides, so turn the pill over and check both.
- It is orange, capsule.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Sold in Canada as Apo-Levofloxacin by Apotex Inc.
In Canada: prescription only.
Ingredients
Active: Levofloxacin (Levofloxacin Hemihydrate)
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
IPX203 350
Carbidopa and Levodopa 87.5 mg / 350 mg
Orange & white, capsule, 23 mm
Used for Parkinson's disease
-
G 369
Topiramate 100 mg
Gray & orange, capsule, 19 mm
Used for bipolar disorder and focal seizures
-
G 368
Topiramate 50 mg
Gray & orange, capsule, 16 mm
Used for bipolar disorder and focal seizures
-
SD TC 5 mg
Tacrolimus 5 mg
Orange, capsule, 21 mm
Used for eczema
-
SD TC 1 mg
Tacrolimus 1 mg
Orange & yellow, capsule, 14 mm
Used for eczema
-
SD TC 0 5 mg
Tacrolimus 0.5 mg
Orange & pink, capsule, 11 mm
Used for eczema
Other Levofloxacin pills
- LEVAQUIN 250 Levofloxacin 250 mg Pink, oval, 15 mm Used for bronchitis and urinary tract infections (UTIs)
- RDY 279 Levofloxacin 250 mg White, capsule, 14 mm Used for bronchitis and urinary tract infections (UTIs)
- TEVA 7291 Levofloxacin 250 mg Pink, oval, 14 mm Used for bronchitis and urinary tract infections (UTIs)
- W 544 Levofloxacin 250 mg Pink, capsule, 14 mm Used for bronchitis and urinary tract infections (UTIs)
- ML 62 Levofloxacin 250 mg Pink, capsule, 15 mm Used for bronchitis and urinary tract infections (UTIs)
- 13 T Levofloxacin 250 mg Pink, capsule, 15 mm Used for bronchitis and urinary tract infections (UTIs)
- I 25 Levofloxacin 250 mg Pink, capsule, 13 mm Used for bronchitis and urinary tract infections (UTIs)
- SZ 985 Levofloxacin 250 mg Brown, octagon, 14 mm Used for bronchitis and urinary tract infections (UTIs)